Introduction

Each year, MIT Technology Review spotlights the most promising young minds pushing the boundaries of science and technology. The 2026 cohort of innovators under 35 features five biotech trailblazers whose work spans from gene editing to brain interfaces, offering a glimpse into the next wave of medical breakthroughs.

What Happened

MIT Technology Review’s annual 35 Innovators Under 35 list once again highlights young researchers transforming their fields. This year, five biotech innovators under 35 are making waves with solutions that range from emergency childbirth care to age-reversing therapies and AI-designed viruses. Their work reflects a shift toward faster, more targeted, and deeply personalized medicine.

Why This Matters

The contributions of these young biotech leaders extend beyond individual projects. Their innovations address pressing global health challenges, reduce costs, and accelerate timelines for treatments that once took decades to develop. By leveraging cutting-edge tools like AI, gene-editing, and materials science, they are reshaping how diseases are prevented, diagnosed, and treated.

Key Takeaways

  • Postpartum hemorrhage device: Paschal Kija’s Mkanda Salama device costs just $70 and stopped bleeding in 73% of women within 20 minutes, offering a low-cost solution for maternal mortality in Tanzania.
  • Flexible brain electrodes: Xiao Yang’s kirigami-inspired, ultra-small electrodes mimic neuron shape and reduce tissue damage, with honeycombed spiral arrays enabling new ways to study brain cells in the lab.
  • Personalized gene-editing therapy: Sarah Grandinette developed a custom gene-editing treatment for baby KJ, who has a rare genetic disorder; the therapy corrected a genetic “misspelling” and the child is now doing well after hospital discharge.
  • Age-reversal eye therapy: Yuancheng (Ryan) Lu’s reprogramming therapy, initially shown to reverse vision loss in aged mice, is now being tested in humans by Life Biosciences, with the first volunteer dosed in June.
  • AI-designed bacteriophages: Samuel King used generative AI to create new viral genetic blueprints; the AI-designed viruses successfully replicated and infected bacteria, demonstrating a potential future for AI-driven drug discovery and environmental cleanup.

Conclusion

These five innovators under 35 illustrate how young scientists are accelerating biotech forward at an unprecedented pace. Their work not only promises new treatments and technologies but also inspires the next generation to tackle health challenges with creativity, urgency, and interdisciplinary tools.